About Nanotether
Nanotether is a Healthcare company based in Cardiff (United Kingdom) founded in 2012, and was acquired by Belluscura in April 2017. Technology for accelerating drug candidates via DNA tethers is provided. Nanotether has raised $4.06 million across 1 funding round from investors including Belluscura and IP Group. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery. Its competitors include Phoremost and Nanna Therapeutics; 1 of its 2 listed competitors has raised funding.
Company details
Nanotether was founded in 2012 in Cardiff, United Kingdom, and operates in the biotechnology sector focused on drug discovery. Variable-length DNA molecules are utilized as tethers to bind test molecules in proximity, enabling miniaturized biological assays with reduced material needs. This approach supports high-throughput screening programs by addressing efficiency challenges in traditional methods.
- Headquarters Cardiff, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Website nanotether.co.uk
- Social LinkedIn
- Acquired by Belluscura (Apr 2017)
- Total Equity Funding$4.06M (USD)
in 1 rounds
- Latest Funding Round$4.06M (USD), Series A
Jun 2012
- InvestorsBelluscura
& 1 more
- Acquired byBelluscura
(Apr 2017)
Funding Insights of Nanotether
Nanotether has successfully raised a total of $4.06M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.06 million completed in June 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.06M
- Total Rounds 1
- Last Round Series A — $4.06M
- First Round $4.06M
(Jun 2012)
- Investors Count 1
All 1 funding rounds of Nanotether with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2012 | $4.06M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in Nanotether
Nanotether has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Belluscura and IP Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and advisory services are offered across multiple sectors. | 2001 | ipgroupplc.com | London, United Kingdom | |
Provider of medical devices for laparoscopic procedures | 2015 | belluscura.com | Dallas, United States |
Investor details for Nanotether
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Nanotether
3 dated milestones of Nanotether across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Nanotether is founded.
- Funding First funding round of $4.1M.
- Exit Acquired by Belluscura.
Competitors of Nanotether
Nanotether has 2 listed competitors in our database, 1 of them funded. They include Phoremost and Nanna Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| phoremost.com | 2015 | Cambridge, United Kingdom | $76.8M | 32 | Phenotypic screening platform developed to identify drug targets and pathways. | |
| nannatherapeutics.com | 2012 | Cambridge, United Kingdom | 14 | In-vitro directed evolution platform is provided for drug discovery. |
Detailed competitors of Nanotether
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Nanotether (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Nanotether
Nanotether was founded in 2012.
Nanotether is headquartered in Cardiff, United Kingdom. It is registered at Cardiff, Wales, United Kingdom.
Nanotether is a funded company, having raised a total of $4.06M across 1 funding round to date. The company's 1st funding round was a Series A of $4.06M, raised on Jun 2012.
Nanotether was founded in 2012 in Cardiff, United Kingdom, and operates in the biotechnology sector focused on drug discovery. Variable-length DNA molecules are utilized as tethers to bind test molecules in proximity, enabling miniaturized biological assays with reduced material needs. This approach supports high-throughput screening programs by addressing efficiency challenges in traditional methods.
Nanotether's top competitors include Phoremost and Nanna Therapeutics.
Nanotether has 2 investors. Key investors include Belluscura, and IP Group.
Yes. Nanotether was acquired by Belluscura in April 2017.